UroGen Stock Based Compensation from 2010 to 2025

URGN Stock

USD 9.36 0.15 1.58%

UroGen Pharma Stock Based Compensation yearly trend continues to be very stable with very little volatility. Stock Based Compensation is likely to grow to about 14.1 M this year. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2014-12-31

Previous Quarter

3.6 M

Current Value

3.5 M

Quarterly Volatility

3 M

Yuan Drop

Covid

Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 17.8 M or Selling General Administrative of 109.1 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or Days Sales Outstanding of 98.77. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.

Check out the analysis of UroGen Pharma Correlation against competitors.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Latest UroGen Pharma's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of UroGen Pharma over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. UroGen Pharma's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

UroGen Stock Based Compensation Regression Statistics

	Arithmetic Mean	10,481,841
	Geometric Mean	3,702,256
	Coefficient Of Variation	108.99
	Mean Deviation	9,227,571
	Median	9,343,000
	Standard Deviation	11,424,478
	Sample Variance	130.5T
	Range	30.3M
	R-Value	0.57
	Mean Square Error	94.5T
	R-Squared	0.32
	Significance	0.02
	Slope	1,366,904
	Total Sum of Squares	1957.8T

UroGen Stock Based Compensation History

	2025	14.1 M
	2024	10.7 M
	2023	9.3 M
	2022	10.6 M
	2021	23.1 M
	2020	28 M
	2019	30 M

Other Fundumenentals of UroGen Pharma

Stock Based Compensation To Revenue

UroGen Pharma Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Net Receivables	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments	Short Term Debt
Total Assets		-0.03	-0.16	-0.08	-0.87	0.8	0.78	0.99	0.96	0.69	0.92	0.78	0.75	0.88	0.91	0.64	0.0	0.91	0.79	-0.71	-0.39
Total Stockholder Equity	-0.03		0.99	-0.78	0.45	-0.01	-0.65	-0.12	-0.23	0.53	0.04	0.43	0.13	-0.13	-0.4	-0.56	0.87	-0.17	-0.44	0.47	0.46
Net Tangible Assets	-0.16	0.99		-0.76	0.53	-0.1	-0.75	-0.25	-0.35	0.45	-0.06	0.35	0.06	-0.21	-0.5	-0.69	0.83	-0.29	-0.55	0.53	0.52
Net Debt	-0.08	-0.78	-0.76		-0.18	-0.27	0.43	-0.06	-0.01	-0.49	-0.26	-0.51	-0.33	-0.08	0.12	0.36	-0.51	0.08	0.23	-0.11	-0.46
Retained Earnings	-0.87	0.45	0.53	-0.18		-0.71	-0.93	-0.9	-0.93	-0.45	-0.8	-0.49	-0.64	-0.92	-0.97	-0.7	0.44	-0.85	-0.89	0.94	0.43
Accounts Payable	0.8	-0.01	-0.1	-0.27	-0.71		0.6	0.83	0.8	0.43	0.88	0.84	0.85	0.78	0.76	0.41	-0.18	0.73	0.64	-0.56	-0.26
Total Liab	0.78	-0.65	-0.75	0.43	-0.93	0.6		0.83	0.87	0.18	0.67	0.31	0.47	0.73	0.94	0.85	-0.54	0.79	0.87	-0.83	-0.58
Total Current Assets	0.99	-0.12	-0.25	-0.06	-0.9	0.83	0.83		0.99	0.63	0.94	0.74	0.76	0.89	0.94	0.69	-0.11	0.9	0.82	-0.77	-0.41
Common Stock	0.96	-0.23	-0.35	-0.01	-0.93	0.8	0.87	0.99		0.56	0.92	0.66	0.72	0.88	0.96	0.74	-0.22	0.88	0.86	-0.83	-0.42
Property Plant Equipment	0.69	0.53	0.45	-0.49	-0.45	0.43	0.18	0.63	0.56		0.65	0.72	0.62	0.69	0.44	0.04	0.47	0.56	0.36	-0.43	0.04
Long Term Debt	0.92	0.04	-0.06	-0.26	-0.8	0.88	0.67	0.94	0.92	0.65		0.83	0.84	0.86	0.83	0.47	-0.09	0.75	0.66	-0.71	-0.24
Short Term Investments	0.78	0.43	0.35	-0.51	-0.49	0.84	0.31	0.74	0.66	0.72	0.83		0.74	0.68	0.58	0.14	0.33	0.64	0.37	-0.33	-0.09
Long Term Debt Total	0.75	0.13	0.06	-0.33	-0.64	0.85	0.47	0.76	0.72	0.62	0.84	0.74		0.77	0.63	0.26	-0.07	0.65	0.57	-0.56	-0.19
Capital Surpluse	0.88	-0.13	-0.21	-0.08	-0.92	0.78	0.73	0.89	0.88	0.69	0.86	0.68	0.77		0.88	0.46	-0.22	0.87	0.83	-0.86	-0.29
Net Receivables	0.91	-0.4	-0.5	0.12	-0.97	0.76	0.94	0.94	0.96	0.44	0.83	0.58	0.63	0.88		0.76	-0.36	0.87	0.87	-0.87	-0.42
Current Deferred Revenue	0.64	-0.56	-0.69	0.36	-0.7	0.41	0.85	0.69	0.74	0.04	0.47	0.14	0.26	0.46	0.76		-0.34	0.71	0.82	-0.56	-0.62
Net Invested Capital	0.0	0.87	0.83	-0.51	0.44	-0.18	-0.54	-0.11	-0.22	0.47	-0.09	0.33	-0.07	-0.22	-0.36	-0.34		-0.06	-0.36	0.55	0.13
Net Working Capital	0.91	-0.17	-0.29	0.08	-0.85	0.73	0.79	0.9	0.88	0.56	0.75	0.64	0.65	0.87	0.87	0.71	-0.06		0.93	-0.67	-0.55
Capital Stock	0.79	-0.44	-0.55	0.23	-0.89	0.64	0.87	0.82	0.86	0.36	0.66	0.37	0.57	0.83	0.87	0.82	-0.36	0.93		-0.78	-0.57
Long Term Investments	-0.71	0.47	0.53	-0.11	0.94	-0.56	-0.83	-0.77	-0.83	-0.43	-0.71	-0.33	-0.56	-0.86	-0.87	-0.56	0.55	-0.67	-0.78		0.27
Short Term Debt	-0.39	0.46	0.52	-0.46	0.43	-0.26	-0.58	-0.41	-0.42	0.04	-0.24	-0.09	-0.19	-0.29	-0.42	-0.62	0.13	-0.55	-0.57	0.27

Click cells to compare fundamentals

About UroGen Pharma Financial Statements

UroGen Pharma investors utilize fundamental indicators, such as Stock Based Compensation, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	10.7 M	14.1 M
Stock Based Compensation To Revenue	0.13	0.12

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of UroGen Pharma Correlation against competitors.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

2.389

Quarterly Revenue Growth

0.209

Return On Assets

(0.21)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Stock Based Compensation from 2010 to 2025

Latest UroGen Pharma's Stock Based Compensation Growth Pattern

UroGen Stock Based Compensation Regression Statistics

UroGen Stock Based Compensation History

Other Fundumenentals of UroGen Pharma

UroGen Pharma Stock Based Compensation component correlations

About UroGen Pharma Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY